Used in the treatment of advanced basal cell carcinoma, particularly for patients with metastatic disease or locally advanced cases that are not suitable for surgery or radiation. It functions by inhibiting the Hedgehog signaling pathway, which is abnormally activated in these cancers. This targeted therapy helps shrink tumors and control disease progression. It is taken orally, offering a non-invasive option for long-term management. Also investigated for use in other cancers driven by Hedgehog pathway activation, such as medulloblastoma and certain skin cancer recurrences.